Gland Pharma Limited CC-Jun25.pdf · 2025-08-05
You indicated that for the GLP -1 products for FY '27, you will be commercializing around 20 million pens and cartridges. So , what kind of a fill/finish pricing are you working with -- so while I understand that the pricing would be dependent on how the end market dynamics play out, but some ballpark number would be helpful here.
Okay. But this 20 million commercialization which will happen in FY '27 will largely be for the RoW market and hence you will book that revenue as part of the RoW business.